Strong Revenue Growth
CeriBell reported Q4 2024 revenue of $18.5 million, reflecting 41% growth over the same period last year. For the full-year 2024, revenue totaled $65.4 million, representing 45% growth over 2023.
High Gross Margin
The company maintained a strong margin profile with a gross margin of 88% in Q4 and 87% for the full year.
Expansion of Active Accounts
CeriBell increased its active account set to 529 accounts by December 31, 2024, adding 25 new accounts in the quarter.
Successful IPO and Strong Cash Position
CeriBell completed a successful IPO in October, resulting in net proceeds of approximately $188 million, ending 2024 with $194.4 million in cash and cash equivalents.
Promising R&D Pipeline
CeriBell is expanding its R&D efforts, with plans to submit a 510(k) application for pediatric patients and developing algorithms for delirium detection, stroke detection, and other neurological conditions.